

**Annual Report**  
**Division of Internal Medicine**  
**April 2005-Mar 31 2006**

## **I      Highlights**

### **Overview**

The past year has been an important year for our division. The newly hired Chief of Medicine, Dr. Ernesto Schiffrin, is an internationally renowned Internist with a strong academic interest in vascular remodeling. The creation of a multi-divisional cardiovascular prevention center will greatly enhance the profile of our division in the community. With Dr. Schiffrin, our division now boasts 4 researchers with greater than 50% time commitment to research, 2 tenured full professors and 1 tenured Associate Professor, 1 Associate Professor (non-tenured) and the rest at Assistant Professor status. Our 11-member division is currently McGill's most productive Internal Medicine group in research and clinical responsibilities while maintaining its share of teaching responsibilities.

Some additional highlights this year include:

Dr. Susan Kahn has become a tenured Associate professor at McGill and has assumed the role of Associate Clinical Research Director of the Lady Davis Institute. She continues in her role as Director of the Thrombosis Clinic and has provided the hospital with best practice guidelines for anticoagulation.

Dr. Michelle Elizov has replaced Dr. Rubin Becker as the site Program Director for core Internal Medicine Residency training. With a Masters degree in Medical Education, Michelle brings new enthusiasm and expertise to this highly important activity.

Dr. Vicky Tagalakis continues to devote more than 50% of her time to thrombosis-related research while also maintaining responsibilities as the University Internal Medicine Fellowship Program Director.

Dr. John Hoffer continues to devote 75% of his time to nutrition-related research. He also offers his unique expertise to the nutritional support team and provides consultation on nutrition in his outpatient clinic.

Dr. Luc Trudeau will be moving his Hypertension clinic to the newly renovated Nun's property. He joins Dr. Schiffrin, Endocrinology, Cardiology and Nephrology in a united fight against cardiovascular disease.

Dr. Joe Raffoul continues to act as our Medical Coordinator for ER admissions. He is also the 7 west CTU director and the Director of our Medical Short Stay Unit. Dr. Raffoul has been a key person in improving emergency and inpatient services for the Department of Medicine.

Dr. Ruxandra Bunea continues to provide teaching and clinical expertise for all the outpatient and inpatient services provided by our division.

Dr. Harvey Chang continues to devote his time and effort to palliative care as Director of the

Palliative care unit as well as caring for palliative patients on 4 west and 2 main.

Dr. Janice Cohen continues her work on the neurological unit and intermediate care.

Dr. Rubin Becker has stepped down, after a 3 year term, as Acting Chief of Medicine. He has also concluded his 12 year term as Program Director to the core Internal Medicine residents. He continues in his role as Chief of this division and also maintains his commitment as Medical Director at Mount Sinai Hospital and Chief of Medicine at the Jewish Rehabilitation Hospital.

The next year's challenges will be to respond to the needs of an expanded medical school class, while building a stronger academic mission and meeting the increasing clinical demands of Internal Medicine. In the past decade, the role of Internal Medicine has become clearer and its importance in health care delivery is increasingly recognized. The Ministry will be making a strong effort to increase the number of trained Internists. Our division will continue to dedicate itself to the new challenges in health care.

### **Patient Care**

The Division provides daily care to over 100 patients in the Medical Holding Area, the Medical Short Stay Unit, the Intermediate Care wards and the Palliative Care Unit. In addition, more than a dozen daily consultations are provided in the Emergency Room and throughout the hospital. There is also a very active outpatient-teaching clinic that is supervised by the Division members. Finally the Division of Internal Medicine has developed special clinics with unique expertise, such as the Hypertension Clinic and the Thrombosis Clinic. As well, expertise in nutritional support is provided both on an outpatient and inpatient basis.

### **Teaching**

The Division of Internal Medicine is home to 1/3 of Medical residents at McGill University with 20 first year residents and up to 11 second year residents and 9 third year residents. Division members supervise both the core residents for their 3-year program and fellows who in their 4<sup>th</sup> and 5<sup>th</sup> years specialize in a career in Internal Medicine. Teaching for residents and medical students is provided in the clinics, the clinical teaching units, the Emergency Room as well as the conference rooms. Two of our members, Drs. Susan Kahn and Vicky Tagalakakis hold Masters degrees in Epidemiology and also teach students and residents how to conduct clinical research and learn to critically appraise scientific literature. Dr. John Hoffer has a PhD in Nutrition and provides a wealth of information on topics related to nutrition. Dr. Michelle Elizov has completed her Masters in Education and has replaced Dr. Rubin Becker as the site Program Director for core Internal Medicine Residency training. Dr. Rubin Becker has stepped down as Program Director after 12 years to the core Internal Medicine residents. He continues in his role as Chief of The Internal Medicine Division. Dr. Vicky Tagalakakis is the McGill Fellowship Program Director for Internal Medicine. Dr. Joe Raffoul is the Director of the 7 West CTU, Director of the Medical Short Stay Unit and acts as the Hospital's Medical Coordinator for admissions, providing the residents with first-hand understanding of the issues related to hospital administration and inpatient management. Dr. Luc Trudeau is a leading expert in Hypertension management and is the Director of the Hypertension clinic, providing extensive lectures on Hypertension. Dr. Harvey Chang was the first physician to run the Palliative Care unit and is currently the Director of the ward providing teaching in this area to students and residents.

## **Research**

Three Internists spend more than 50% of their time conducting research. All 3 have been highly successful in obtaining major peer-reviewed grants and career awards, totaling more than \$1.5 million dollars this year. Drs. Susan Kahn and Vicky Tagalakakis have built impressive reputations in the field of thromboembolic disease while Dr. John Hoffer has extensive research productivity in the area of nutrition. Most of the other internists manage to participate in clinical research while attending to their overwhelming clinical responsibilities and teaching obligations.

## **Special Programs**

The Thrombosis Clinic under the leadership of Dr. Susan Kahn, the Founding Director, is an excellent example of the synergy that the Division of Internal Medicine has with other Divisions participating in this special area of expertise. Members of Hematology and Pulmonary work with Drs. Kahn and Tagalakakis to provide a rich clinical, research and teaching environment to evaluate thromboembolic conditions and recommend the optimal treatment strategies.

The Nutrition Clinic and Nutritional Support Service benefit greatly from Dr. John Hoffer's lifelong commitment to this field.

The Hypertension Clinic, under the leadership of Dr. Luc Trudeau is invaluable to patients suffering from this common disorder.

## **II Evaluation of Past Academic Year**

### **a. Faculty**

Dr. Rubin Becker, Director, Division of General Internal Medicine  
Dr. Ruxandra Bunea  
Dr. Harvey Chang  
Dr. Janice Cohen  
Dr. Michelle Elizov  
Dr. John Hoffer  
Dr. Susan Kahn  
Dr. Joe Raffoul  
Dr. Ernesto Schiffrin  
Dr. Luc Trudeau  
Dr. Vicky Tagalakakis

### **Support Staff:**

Ms. Wanda Kagan  
Ms. Michelle Laurin  
Mrs. Angie Sacratini  
Mrs. Audrey Weizmann

## **b. Clinical Activities**

1. Internal Medicine Out-Patient Clinic:
  - 1/2 day clinic per week
  - Drs. R. Becker, R. Bunea, M. Elizov, J. Raffoul, L. Trudeau, V. Tagalakis, Dr. J. Hoffer
2. Hypertension Clinic:
  - 1 clinic per week
  - Drs. L. Trudeau

Thrombosis Clinic:

  - 2 day clinic per week
  - Drs. S. Kahn, V. Tagalakis
4. MSTU:
  - ER Consultations
  - Inpatient Consult Service
  - Drs. R. Becker, R. Bunea, M. Elizov, J. Hoffer, S. Kahn, J. Raffoul, V. Tagalakis, L. Trudeau
  - Nutritional Support Team Consultation:
  - Dr. John Hoffer
5. 2 Main, 2NE, 4 Main, 4NW
  - Intermediate and Palliative Care:
  - Dr. Harvey Chang, Dr. Janice Cohen & Dr. Ruxandra Bunea
6. Internal Medicine Consults for Jewish Rehabilitation Hospital:
  - Dr. Rubin Becker and Dr. Joe Raffoul
7. Link with Mount Sinai Hospital Palliative Care:
  - Dr. Rubin Becker

## **c. Honors & Awards**

Dr. Susan Kahn has been promoted to Associate Professor with tenure. She has also received a renewal of her FRSQ Chercheur-Boursier award (2005-2009). In 2005, she received the Heart and Stroke Foundation of Quebec Pfizer Award of Research Excellence (for researcher who achieves highest rating for a scientific research project) \$25,000.

Dr. Tagalakis continues to hold an FRSQ Chercheur Boursier Young Researcher Development award and young Junior 1 researcher award.

## **d. Teaching Activities**

- IIM (Link), 7 weeks/year: Dr. V. Tagalakakis
- CTU Ward Attending, 1 month/year: Drs. R. Becker, R. Bunea, M. Elizov, J. Hoffer, S. Kahn, J. Raffoul, L. Trudeau, V. Tagalakakis
- AIMC for residents and students: Preceptor for residents in Internal Medicine Clinic (4 clinics/week, 4-5 residents/students per clinic): Drs. R. Becker, J. Raffoul, L. Trudeau, M. Elizov, Dr. R. Bunea, Dr. J. Hoffer, Dr. V. Tagalakakis
- CONSULT SERVICE:
  - Resident supervision  
Drs. R. Becker, R. Bunea, M. Elizov, J. Hoffer, S. Kahn, J. Raffoul, V. Tagalakakis, L. Trudeau
- ER/MSTU:
  - Resident supervision  
Drs. R. Bunea, J. Hoffer, S. Kahn, J. Raffoul, V. Tagalakakis L. Trudeau, M. Elizov,
- CORE LECTURES:
  - Core Lecturer in Internal Medicine, Internal Medicine Residency Program (10 hours/year).  
Drs. R. Becker, M. Elizov J. Hoffer, S. Kahn, J. Raffoul, L. Trudeau, V. Tagalakakis
- INTERNAL MEDICINE Division Rounds  
Drs. R. Becker, R. Bunea, H. Chang, J. Cohen, J. Hoffer, S. Kahn, J. Raffoul, V. Tagalakakis, L. Trudeau
- 2005 Group Leader, Evidence Based Medicine course, Faculty of Medicine, McGill University  
Dr. S. Kahn
- 2005 Group Leader, Introduction to Epidemiology, Faculty of Medicine, McGill University  
Dr. S. Kahn

#### **e. Service to Academic Community and other Contributions**

##### **Hoffer, L. John**

##### **Invited lectures outside McGill**

\*Natick, MA: Optimum Protein Intake in Hypocaloric States. Workshop on Optimization of Assault Rations, Committee on Military Nutrition Research, Food and Nutrition

\*Ottawa, ON, Rational Vitamin Therapy for Homocysteine Reduction. Nutritional Medicine Today, 34<sup>th</sup> Annual International Conference, May 14, 2005

##### **Teaching rounds at the JGH**

Chronic renal failure and homocysteine. Nephrology Divisional Rounds, March 24, 2005  
The biochemistry and pharmacology of vitamins for homocysteine reduction. Endocrine

Division Rounds, Jewish General Hospital, April 21, 2005

### **McGill and JGH Hospital Committee work**

SMBD-Jewish General Hospital Research and Ethics Committee  
SMBD-Jewish General Hospital Department of Medicine Promotions Committee  
Department of Medicine, McGill University Promotions Committee  
Department of Medicine, Users Committee, McGill Mass Spectrometry Laboratory

### **National or International Committee or Scholarly Participation**

- \*Editorial Board, *American Journal of Physiology: Regulatory Integrative and Comparative Physiology* (June 1, 2002 - present)
- \*CIHR Metabolism Committee, Scientific Officer, Metabolism Committee, May 2005.
- \*Bethesda, Maryland, American Society for Clinical Nutrition, Member of Budget and Finance Committee (April 2004- present)

## **Susan Kahn**

### **Teaching rounds**

#### **McGill Departments**

- Developing and promoting excellence in clinical and epidemiological research in a Department of Medicine. Jewish General Hospital, Department of Medicine Retreat. June 9, 2006.
- VTE Prophylaxis in the Surgical Patient. Surgery Grand Rounds, Jewish General Hospital. June 8, 2006.
- The SOX trial and Bio-SOX studies: A research program aimed at improving outcomes after venous thrombosis. Department of Clinical Epidemiology and Community Studies, St. Mary's Hospital Center May 11, 2006.
- VTE Prophylaxis guidelines: What, why, how. VTE Awareness Week Medical Rounds, Jewish General Hospital. May 4, 2006.
- Thrombophilia and Women's Health. Internal Medicine Rounds, Jewish General Hospital. April 21, 2006.
- Thrombophilia in Ob/Gyn. Departments of Obstetrics and Gynecology, Sir Mortimer B. Davis - Jewish General Hospital, and St. Mary's Hospital Center: "Practical Gynecology & Obstetrics 2006 --Symposium: Comprehensive Review for Obstetricians, Gynecologists and Family Physicians". March 17, 2006.
- Thrombophilia and Women's Issues. 34<sup>th</sup> Annual Thursday Evening Learning Series, Centre for Continuing Medical Education, Faculty of Medicine, McGill University. February 2, 2006.
- Update on peri-op DVT prophylaxis. Core Medicine Teaching rounds, McGill University Health Centre. November 17, 2005.
- Trials and tribulations-changing SOX on the run. Clinical Epidemiology Research Rounds, Jewish General Hospital. April 20, 2005.

## **Outside McGill/National**

- The SOX Trial: Improving outcomes after DVT. Thrombosis Round, Ottawa Civic Hospital. Ottawa, Ontario. March 2, 2006.
- Moderator, Update on Venous Thromboembolism. 5<sup>th</sup> Annual Meeting of the Société des Sciences Vasculaires du Québec. Montreal, Quebec. November 25, 2005.
- Difficult cases in thrombosis. Centre Hospitalier. Rouyn-Noranda, Quebec. September 27, 2005.
- Review of ACCP 2004 guides for thromboprophylaxis: what is new, what is different. Centre Hospitalier. Rouyn-Noranda, Quebec. September 27, 2005.
- The Montreal Birth Cohort. Birth Cohorts and Determinants of Childhood Obesity CIHR Workshop. Ottawa, Ontario. October 11, 2005.
- Thromboprophylaxis in Orthopedic Surgery Patients. Grand Rounds, Catherine Booth Hospital. Montreal Quebec. April 1, 2005.

## **International**

- The post-thrombotic syndrome: Why it matters. Blood in Motion: Update in Prevention and Diagnosis of Deep Vein Thrombosis and Pulmonary Embolus, Management of the disease and its sequelae. The Western Pennsylvania Hospital Conference Center, Pittsburgh, Pennsylvania, USA. May 13, 2006.
- Who gets venous thromboembolism and why. Plenary Session, Society of Interventional Radiology Annual Scientific Meeting. Toronto, Ontario. March 31, 2006.
- The post-thrombotic syndrome: the forgotten morbidity. Portland Anticoagulation Consortium. Portland, Oregon, USA. September 7, 2005.
- The post-thrombotic syndrome. Northwest Anticoagulation Consortium. Seattle, Washington, USA. September 6, 2005.
- The post-thrombotic syndrome: the forgotten morbidity. Anticoagulation Forum 8<sup>th</sup> National Conference. Orlando, Florida, USA. May 6, 2005.
- Post-thrombotic syndrome: pathophysiology, prevention and prognosis. 6th Annual Antithrombotic Therapy Symposium. Dearborn, Michigan, USA. March 21, 2005.

## **McGill and JGH Hospital Committee work**

- Chair, Dry Lab Space Committee (2006)
- Member, Search Committee for Head of Radiology, Jewish General Hospital (2006)
- Member, Research Management Committee, Lady Davis Institute for Medical Research, Jewish General Hospital (12hrs/year) (2005-present)
- Search Committee, Director of Research, and Lady Davis Institute for Medical Research, Jewish General Hospital (2005-present)
- Associate Director, Center for Clinical Epidemiology and Community Studies, Lady Davis Institute for Medical Research (2004-present)
- Director and Founder, Thrombosis Clinic, SMBD Jewish General Hospital (1998-present)
- Director of Resident Research, Internal Medicine Residency Training Program, SMBD-Jewish General Hospital (1997-present)
- Interviewer, Internal Medicine Residency Training Program, SMBD-Jewish General Hospital (1996-present)
- Member, Executive Committee of McGill Division of General Internal Medicine (2006-)

- Member, Research Ethics Committee (60 hrs/year) (2001- 2005)
- Member, Search Committee, McGill University Health Centre Director of Clinical Epidemiology (2005 – present)
- Member, McGill Committee for the Royal College Clinical Investigator Program (2005)
- Member, Executive Committee, Department of Medicine (12 hrs/year) (2000- present)
- Associate Professor of Medicine with tenure (2005-present)
- Member, McGill Faculty of Medicine Postgraduate Awards Committee (2005-present)
- Member, Search Committee for McGill Head of General Internal Medicine (2004-2005)
- Member, Urology Departmental Review Committee (12 hrs)
- Panel Member, CIHR Randomized Controlled Trials Grants Committee (4-6 days/yr) (2003- present)
- Member, Science Advisory Committee on Human Reproductive Therapies, Therapeutic Product Directorate, Health Canada (2003- present)
- Member, Executive Committee, Société des Sciences Vasculaires du Québec (2002- 2006)
- Member, Scientific Council, Société des Sciences Vasculaires du Québec (2002- 2006)

### **National or International Committee or Scholarly Participation**

- Director, Research Axis in Thromboembolic Disorders, FRSQ Cardiovascular Research Network (2001-present)
- Panel Member, Chapter on Antithrombotic Therapy for Venous Thromboembolic Disease; in Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines (8th Edition) (2005-2007)
- Chair, BioSOX Substudy Steering Committee (HSFC-funded) (2005-present)
- Member, Evaluation of Trellis Clot Extraction Device (STRIDE Trial) Steering Committee (2004-present)
- Member, Selective D-dimer testing for DVT diagnosis (SELECT Trial) Steering Committee (HSFC-funded) (2004-present)
- Member First Degree relatives Thrombosis Risk (FDR Study) Steering Committee (HSFC-funded) (2003-present)
- Member, Recurrent Venous Thromboembolism Risk Stratification Evaluation (REVERSE Study) Steering Committee (CIHR-funded) (2003-present)
- Chair, Compression stocking to prevent post-thrombotic syndrome (SOX Trial) Steering - Committee (CIHR-funded) (2003-present)

### **Other Contributions:**

- Invited Reviewer for: JAMA, The Lancet, Annals of Internal Medicine (ranked by Editor to be among top 10% of reviewers), American Journal of Medicine, Canadian Medical Association Journal, Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis, Journal of Clinical Epidemiology, Journal of General Internal Medicine, PharmacoEconomics, Journal of Respiratory Diseases, Obstetrics and Gynaecology, Thrombosis Research (1999-present)
- Research abstract reviewer for the American Society of Hematology (2005) Annual Meeting 2005 (Pathophysiology of Thrombosis section)
- Panel Member, CIHR Randomized Controlled Trials Committee (4 days/yr) (Internal Reviewer) (2003-2006)



## **Vicky Tagalakis**

### **3. Invited Lectures, Talks, and Presentations**

#### **McGill Departments**

-Aspirin resistance in diabetics. Endocrinology Grand Rounds. SMBD-Jewish General Hospital, Montréal, Canada. 2005

-Thrombosis and cancer. Medical Grand Rounds. SMBD-Jewish General Hospital, Montréal, Canada 2005

- Determining incidence and predictor of DVT in lung cancer patients. Clinical epidemiology research rounds, Centre for Epidemiology and Community Studies. SMBD-Jewish General Hospital. McGill University, Montréal, Canada 2006

-Determining incidence and predictor of DVT in patients with non-small cell lung cancer. Pulmonary Grand Rounds. SMBD-Jewish General Hospital. McGill University, Montréal, Canada 2006

-Thromboembolic disease in pregnancy. Resident academic half day, SMBD-Jewish General Hospital. McGill University, Montréal, Canada 2006

#### **Outside McGill**

##### **National**

-Exploring sex and gender determinants of venous thromboembolism. 2<sup>nd</sup> annual GENESIS (Gender and Sex determinants of cardiovascular diseases: From Bench to Beyond) meeting. Montréal, Canada. 2006

##### **International**

-The risk of urogenital cancer associated with warfarin use. Oral presentation. International Society of Epidemiology. Lisbon Portugal, August 23-27<sup>th</sup>, 2006.

#### **Teaching Rounds**

-Determining incidence and predictor of DVT in lung cancer patients. Clinical epidemiology research rounds, Centre for Epidemiology and Community Studies. SMBD-Jewish General Hospital. McGill University, Montréal, Canada (2006)

-Aspirin resistance in diabetics. Endocrinology Grand Rounds. SMBD-Jewish General Hospital, Montréal, Canada (2005)

-Thrombosis and cancer. Medical Grand Rounds. SMBD-Jewish General Hospital, Montréal, Canada (2005)

#### **McGill and JGH Hospital Committee work**

-Program Director General Internal Medicine, McGill University (2003-present)

-Research associate, Centre for Clinical Epidemiology and Community Studies, Lady Davis Institute, SMBD-Jewish General Hospital (2002-present)

-Assistant Professor, Department of Medicine, Faculty of Medicine, McGill University  
(2001-present)

**f. Consulting Activities:**

Items marked with \* would fit your definition of “consulting” but none of this was paid.

**g. Research**

**Hoffer, L. John**

**Peer-Reviewed Grants**

CIHR Operating Grant MOP-8725: Nutritional Effects on Amino Acid and Protein Metabolism in Man

2004-5	123,149
2005-6	123,149
2006-7	123,149
2007-8	61,574

Lotte & John Hecht Memorial Foundation: Phase I-II Study of Intravenous Ascorbate Infusions in Cancer Patients

2005-6	157,761
2006-7	157,761

CIHR Operating Grant MOP-53072: Nutritional supplementation in renal disease

2004-5	80,696
--------	--------

CIHR Major Equipment Grant MME-6712: Biomedical gas chromatography-mass spectrometry maintenance (Principal Investigator: WS Powell, with OA Mamer, A Bateman, H Bennett, DS Rosenblatt, CR Scriver, and E Treacy)

2004-5	105,996
2005	26,499

**Kahn, Susan**

**Peer-Reviewed Grants**

**PERSONAL SUPPORT AWARDS**

2006-2011	<b>CIHR - Research Resource Grant Program</b> Furthering Innovation in Thrombosis Research Wells P (PI)/ <b>Kahn SR (co-applicant)</b> \$624,466
-----------	---

2006-2011	<b>CIHR</b> A Double Blind Randomized Controlled Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism - PERIOP 2 Kovacs M, Rodger M (co-PIs)/ <b>Kahn SR (co-applicant)</b> \$2,300,000
2006-2011	<b>CIHR</b> The Thrombophilia in Pregnancy Prophylaxis Study (TIPPS) Rodger M (PI)/ <b>Kahn SR (co-applicant)</b> \$2,349,792
2005-2009	<b>Fonds de Recherche en Santé du Québec (FRSQ)</b> Chercheur Boursier Clinicien (Clinical Investigator Award) Senior <i>Epidemiologic research in venous thromboembolism: Outcomes and Mechanisms</i> <b>Ranking: 1<sup>st</sup> of 8</b> \$39,000 per year
2005-2006	<b>Heart and Stroke Foundation of Quebec Pfizer Award of Research Excellence</b> for researcher who achieves highest rating for a scientific research project \$25,000
2005	<b>Special Research Recognition Award, McGill University, Faculty of Medicine</b> \$5,000
2001-2005	<b>Fonds de Recherche en Santé du Québec (FRSQ)</b> Chercheur Boursier Clinicien (Clinical Investigator Award) Junior 2 <i>Epidemiology of Venous Thromboembolism: Mechanisms and Long term Outcomes</i> <b>Ranking: 1<sup>st</sup> of 15</b> \$36,000 per year
2005-2008	<b>CIHR</b> PROTECT: PROphylaxis of ThromboEmbolism in Critical Care Trial Cook DJ (PI)/ <b>Kahn SR (co-applicant)</b> \$4,880,347
2005-2008	<b>Heart and Stroke Foundation of Canada</b> The Role of Inflammation and Thrombophilia in the Post-Thrombotic Syndrome: The BIO-SOX Study <b>Kahn SR (PI)</b> / Wells PS (co-PI)/ Kovacs MJ/ Anderson DR/ Genest J/Shapiro S/Rodger MA <b>Ranking: 1<sup>st</sup></b> \$298,000
2004-2009	<b>Heart and Stroke Foundation of Canada - Group Grant</b> Thrombophilia: from bench to bedside to health economics and policy Well PS (PI)/ <b>Kahn SR (co-applicant)</b> \$1,250,000

- 2004-2008     **Heart and Stroke Foundation of Canada**  
 Selective D-Dimer testing for diagnosis of deep vein thrombosis  
 Kearon (PI)/ Bates/ Linkins/ Ginsberg/ **Kahn (co-applicant)**/ Douketis/  
 Julian/ O'Brien/ Turpie  
 \$702,941
- 2004-2008     **CIHR-RCT**  
 Does low dose oral vitamin K reduce the risk of bleeding, without causing  
 thrombosis, in patients with warfarin-associated coagulopathy: A  
 randomized clinical trial  
 Crowther (PI)/ Kearon/ Garcia/ Blostein/ Selby/ Wells/ Ginsberg/ **Kahn**  
**(co-applicant)**/ Anderson/ Ageno/ Kovacs  
 \$495,663
- 2003-2008     **CIHR**  
 Compression stockings and COX-II inhibitors to prevent post-thrombotic  
 syndrome: The SOX multicenter Trial  
**Kahn (PI)**/ Ginsberg/ Wells/ Anderson/ Rodger/ Johri/ Shapiro/ Kovacs/  
 Tagalakis  
 \$1,331,859
- 2003-2006     **CIHR, Heart and Stroke Foundation of Canada**  
 Recurrent venous thromboembolism risk stratification evaluation:  
 REVERSE Study.  
 Kovacs M (PI)/ **Kahn (co-applicant)**/ Rodger/ Wells/ Anderson  
 \$597,604
- 2003-2005     **Heart and Stroke Foundation of Canada**  
 Association study- Putative thrombophilia and Factor VIII  
 Wells (PI)/ **Kahn (co-applicant)** and others  
 \$175,439
- 2003-2005     **National Cancer Institute of Canada (NCIC)**  
 The effect of warfarin on the risk of urogenital cancer  
 Tagalakis (PI)/ Collet/ **Kahn(co-applicant)**/ Hanley/ Blostein  
 \$112,006
- 2002-2005     **CIHR**  
 Inherited thrombophilia and endothelial dysfunction in preeclampsia  
**Kahn (PI)**/ Kramer / Platt / McNamara  
 Ranking: 3rd of 58, Public, Community and Population Health Committee  
 \$145,515
- 2002-2005     **Heart and Stroke Foundation of Canada**  
 Management of the postphlebotic syndrome  
 Ginsberg (PI)/ **Kahn (co-applicant)**/ Kearon/ Julian

\$234,726

1998-ongoing **Lady Davis Institute for Medical Research, SMBD Jewish General Hospital** Internal salary award  
\$25,000 per year, renewable

2001-ongoing **FRSQ**  
Infrastructure support to initiate and head an Axis in Thromboembolism Research within the FRSQ Cardiovascular Research Reseau (Network) **Kahn (Axis head)**/ 16 other Quebec thrombosis researchers  
\$21,000 per year

2001-2005 **CIHR**  
D-dimer and compression ultrasonography for the diagnosis of recurrent DVT  
Bates (PI)/ **Kahn (co-applicant)**/ Crowther/ Ginsberg/ Kearon/ Kovacs  
\$620,000

2001-2007 **FRSQ (co-funded by unrestricted grant-in-aid, Sanofi Pharma)**  
A prospective cohort study of the postphlebotic syndrome after deep vein thrombosis: Evaluation of risk factors, costs, and impact on quality of life.  
**Kahn (PI)**/ Solymoss/ Johri/ Kassis/ Shrier / Desjardins/ Roussin  
\$1,311,144

## **ii. Unrestricted grants-in-aid, Industry**

2003 Multicentre Chart Audit of Utilization of Risk Assessment and Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients in Canada: The CURVE Study (Aventis Pharma) Panju (PI)/ **Kahn (co-I, Steering Committee member)**/ Pineo/ Turpie/ Geerts/ Desjardins: \$285,085

## **iii. Pharmaceutical Industry-Initiated Grants**

2004-2005 Van Gogh Studies of idraparinux to treat (1) DVT (2) PE (Sanofi + Organon) **Kahn (Site Investigator)**

2003-2005 LAIM Study (XRP4563C-3501). A double blind, placebo-controlled, parallel multicenter study on extended VTE prophylaxis in acutely ill medical patients (Aventis Pharma) **Kahn (Site Investigator)**

**Tagalakis, Vicky**

### **Career Award**

2005-2008 Fonds de la Recherche en Sante du Quebec, \$29,034

### **Grants applied for**

2006-2008 **GENESIS 2005 pilot project award (CIHR)**“Exploring sex and gender

determinants of venous thrombosis in Quebec men and women: Preliminary evaluation of the validity of the RAMQ database for the diagnosis of venous thromboembolism” Tagalakis (PI)/Kahn/Hirsch/Tamin , \$8000.00

### Peer-Reviewed Grants

- 2005-06      GENESIS 2005 pilot project award (CIHR)  
“Exploring sex and gender determinants of venous thrombosis in Quebec men and women: Preliminary evaluation of the validity of the RAMQ database for the diagnosis of venous thromboembolism”  
Tagalakis (PI)/Kahn/Hirsch/Tamin  
\$8000.00
- 2003-2006      National Cancer Institute of Canada  
“The effect of warfarin on the risk of urogenital cancer”  
Tagalakis (PI)/Collet/Kahn/Hanley/Blstein  
\$270, 000.00
- 2003-2008      CIHR Operating Grant  
“Stockings and COX-II inhibitors to prevent post-thrombotic syndrome: THE SOX Trial”  
Kahn (PI)/Tagalakis (co-investigator)/Shapiro/Johri  
\$1,300,000.00

### h. Publications

#### Refereed Publications:

-- **Hoffer LJ**, Saboohi F, Golden M, Barré PE. Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease. *Metabolism* 54:835-40, 2005

--**Kahn SR**. The post-thrombotic syndrome: progress and pitfalls. *Br J Haematol*. 2006 Aug;134(4):357-65.

--**Kahn SR**. Frequency and determinants of the post-thrombotic syndrome after venous thromboembolism. *Curr Opin Pulm Med* 2006;12:299-303.

--**Kahn SR**. Review: Horse chestnut seed extract for chronic venous insufficiency. *ACP Journal Club* 2006; 145(1):20.

--**Kahn SR**, Desmarais S, Ducruet T, Arsenault L, Ginsberg JS. Comparison of the Villalta and Ginsberg clinical scales to diagnose the post-thrombotic syndrome: correlation with patient-reported disease burden and venous valvular reflux. *J Thromb Haemost* 2006;4:907-908.

--\*Elman ER, **Kahn SR**. The post-thrombotic syndrome after upper extremity deep venous

thrombosis: A systematic review. Thrombosis Research 2006;117(6):609-614.

--**Kahn SR**. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thrombosis Thrombolysis 2006;21(1):41-48.

--\*Schiff RL, **Kahn SR**, Shrier I, Strulovitch C, Hammouda W, Cohen E, Zukor D. Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis. Chest 2005;128(5):3364-3371.

--\*Fox EA, **Kahn SR**. The relationship between inflammation and venous thrombosis: A systematic review of clinical studies. Thromb Haemost 2005;94(2):362-365.

--**Kahn SR**, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M and Shrier I. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Int Med 2005, 165(10):1173-1178.

--Kovacs MJ, Kearon C, Julian J, MacKinnon B, Douketis J, Demers C, Wells P, Turpie AGG, Anderson DR, **Kahn SR**, van Nguyen P, Green D, Kassis J, Geerts W, Ginsberg JS. Influence of warfarin use on symptoms of fatigue: Findings of a randomized trial. Ann Pharmacother 2005, 39(5):840-842.

--**Kahn SR**, Kearon C, Julian J, MacKinnon B, Kovacs M, Wells P, Crowther M, Anderson DR., van Nguyen P, Demers C, Solymoss S, Kassis J, Geerts W, Rodger M, Hambleton J, Ginsberg JS for the ELATE Investigators. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep venous thrombosis. J Thromb Haemost 2005, 3(4):718-723.

--Shrier I, **Kahn SR**. Effect of physical activity in patients after recent deep venous thrombosis: a cohort study. Medicine & Science in Sports & Exercise 2005, 37(4):630-634.

--**Kahn SR**, Elman EA, Bornais C, Blostein M, Wells PS. Post-thrombotic syndrome, functional disability and quality of life after upper extremity deep venous thrombosis in adults. Thromb Haemost., 93:499-502, 2005

--Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS for the THRIVE Treatment Study Investigators (includes **Kahn SR**). Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis: A Randomized Trial. JAMA, 293:681-689, 2005

### **Other Publications:**

--Lang E, Kovacs G, Stiell I, Afilalo M, **Kahn SR**, Dreyer J, Snyder B, Anderson D. Computerized Tomographic Pulmonary Angiography Compared With Ventilation Perfusion Lung Scanning as Initial Diagnostic Modality for Patients With Suspected Pulmonary Embolism: A Randomized Controlled Trial. Oral presentation, International Conference on Emergency Medicine (ICEM), June 2006, Halifax, Nova Scotia. Oral presentation at the

Annual Meeting of the Society for Academic Emergency Medicine, May 2006, San Francisco, California.

--Afilalo M, Lang E, Tselios C, Guttman A, Colacone A, **Kahn SR**, Hirsch A, Xue X, Pleasance S, Anderson D. Length of Stay Considerations When Selecting An Imaging Strategy for High-risk Patients With Suspected Pulmonary Embolism: An Analysis of the Pulmonary Embolism Diagnostic Study. Poster presentation, International Conference on Emergency Medicine (ICEM). June 2006, Halifax, Nova Scotia. Oral presentation, Annual Meeting of the Society for Academic Emergency Medicine, May 2006, San Francisco, California.

--**Kahn SR**, Desmarais S, Ducruet T, Arsenault L, Ginsberg JS and VETO Study Investigators. Comparison of performance of two clinical scales to diagnose the post-thrombotic syndrome: Correlation with patient-reported disease burden and valvular reflux. 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #4114.

--**Kahn SR**, Vydykhan T, Lamping DL, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Ginsberg JS, Desjardins L, Johri M and Shrier I. Determinants of health-related quality of life after deep venous thrombosis: Two-year results from a Canadian multicenter prospective cohort study (The VETO Study). Oral Presentation, 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #585.

--Lazo-Langner A, Clement AM, Robinson S, Smith G, Kovacs M, Blostein M, **Kahn SR**, Kingdom J, Demers C, Solymoss S, Khurana R, Rey E, Wells PS and Rodger MA. Prophylactic Low Molecular Weight Heparin (LMWH) during pregnancy is not associated with an increased risk of osteoporosis. The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) Bone Mineral Density (BMD) substudy. Oral Presentation, 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #548.

--**Kahn SR**, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I, Lamping DL and Ginsberg JS. Incidence, timing of onset and severity of post-thrombotic syndrome after acute symptomatic deep vein thrombosis: Two-year results from a Canadian multicenter prospective cohort study (The VETO Study). Poster Presentation, 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #1636.

--**Kahn SR**, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Ginsberg JS, Desjardins L, Johri M, Lamping DL and Shrier I. Predictors of the development of post-thrombotic syndrome after acute symptomatic deep vein thrombosis: Two-year results from a Canadian multicenter prospective cohort study (The VETO Study). Poster Presentation, 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #1635.



--Anderson DR, Wells PS, **Kahn SR**, Rodger M, Kovacs MJ, Morris T, Pleasance S for the PEDS Investigators. Computerized Tomographic Pulmonary Angiography Compared with Ventilation-Perfusion Lung Scanning as Initial Diagnostic Modality for Patients with Suspected Pulmonary Embolism: A Randomized Controlled Trial. Poster Presentation, 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #1619.

--Crowther MA, Garcia D, Ageno W, Witt DM, Schulman S, Blostein M, Kovacs MJ, Kearon C, Anderson D, Wells P, Ginsberg JS, Selby R, Wang L and **Kahn SR**. Use of low dose oral vitamin K in the treatment of patients with INR values of more than 10.0. Oral Presentation, 47th Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 3-6, 2005. Blood 2005; 106: Abstract #547.

--**Kahn SR**, Lamping DL, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L. The VEINES-QOL/Sym questionnaire is a valid and reliable measure of quality of life in patients with deep venous thrombosis. Poster Presentation, XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 6-12, 2005. J Thromb Haemost, Abstract #P1634, 2005

--\*Tagalakakis V, **Kahn SR**, Libman M, Blostein M, Solymoss S, Miller M. Thrombophilia is not a risk factor for peripheral intravenous infusion-associated thrombophlebitis. Poster Presentation, XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 6-12, 2005. J Thromb Haemost, Abstract #P0533, 2005

--**Kahn SR**, Fox E\*. The relationship between venous thrombosis and inflammation: a systematic review of clinical studies. Poster Presentation, XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 6-12, 2005. J Thromb Haemost, Abstract #P0440, 2005

--Bates SM, Julian J, Kearon C, **Kahn SR**, Geerts W, Kovacs M, Crowther MA, Gerdes V, Ginsberg JS. Derivation of a clinical model to predict the likelihood of recurrent deep vein thrombosis. Poster Presentation, XXth Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 6-12, 2005. J Thromb Haemost, Abstract #P2237, 2005

--Vydykhan TN, Shapiro S, **Kahn SR**, on behalf of the SOX Trial Steering Committee. The Decision to Discontinue the Celecoxib Intervention in the SOX Trial: Process and Implementation. Joint meeting of the Society for Epidemiologic Research and Canadian Society for Epidemiology & Biostatistics, Toronto, June 2005. American Journal of Epidemiology 2005; 161 (Suppl): S74: Abstract #296.

--Shrier I, **Kahn SR**. Effect of physical activity after recent deep venous thrombosis. Oral presentation, 52nd Annual meeting of the American College of Sports Medicine, Nashville Tennessee, June 1-4, 2005. Abstract Number: 05-SA-740-ACSM.

--Shrier I, **Kahn SR**. Effect of physical activity after recent deep venous thrombosis: A cohort study. Oral presentation, Canadian Academy of Sport Medicine/OMA, Sport Medicine Section, Annual Symposium, Ottawa, Ontario, February 9-12, 2005. Clin J Sport Med 2005, 15(5): 396-396.

--TIPPS investigators (includes **Kahn SR**). Prevalence of Factor V Leiden and prothrombin gene mutation in women with a history of placenta mediated pregnancy complications. NASOM Meeting, Reno, Nevada, February 2005.

--**Tagalakis V**, Kahn SR Llibman M, Blostein M. Thrombophilia is not a risk factor for peripheral vein infusion thrombophlebitis. XXth Congress of the International Society on Thrombosis and Haemostasis 2005.

--Vydykhan TN, Shapiro S, Kahn SR, **Tagalakis V** on behalf of the SOX Trial Steering Committee. The decision to discontinue the celecoxib intervention in the SOX Trial: Process and implementation [abstract]. Am J Epidemiology 2005; 161(Suppl):S74. Abstract 296

-- Levi D, **Tagalakis V**, Cohen V, Agulnik A, Small D. The Risk of Deep Vein Thrombosis in Lung Cancer Patients. Poster presentation at the ATS International Conference in San Diego, California, May 19th-24<sup>th</sup> 2006.

--**Tagalakis V**, Levi D, Agulnik A, Small D. The Risk of Deep Vein Thrombosis in Patients with Non-small cell lung cancer. Poster presentation at the ASCO conference in Atlanta, Georgia, June 2-4th 2006.

-- **Tagalakis V**, H. Tamim, J. Collet, S. R. Kahn, M. Blostein, and J. A. Hanley  
The effect of warfarin on the risk of prostate cancer. Journal of Clinical Oncology. ASCO Meeting Abstracts 2006 ;24 (18S): 14524 .

-- D. Levi, **V. Tagalakis**, V. Cohen, J. Agulnik, G. Kasymjanova, and D. Small  
Determining incidence and predictors of deep vein thrombosis in patients with non- small cell lung cancer. Journal of Clinical Oncology. ASCO Meeting Abstracts 2006; 24 (18S): 7159.

### **Manuscripts Submitted**

-- **Tagalakis V**. Anti-cancer properties of warfarin: a review article, submitted to American Journal of Medicine 2006

### **Manuscripts in Preparation**

-- **Tagalakis V**, Levy D, Agulnik J, Cohen V, Small D. Assessing the incidence of deep vein thrombosis in patients with non-small lung cancer: A prospective cohort study.

--**Tagalakis V**, Tamim H, Kahn SR, Collet JP, Hanley M, Blostein M The effect of warfarin use on the risk of urogenital cancer: a population based case-control study